Do therapeutic strategies targeting chronic inflammation reduce residual cardiovascular risk in high-risk patients?
High-sensitivity C-reactive protein is a practical biomarker for assessing low-grade chronic inflammation, and anti-inflammatory therapies represent a promising approach for reducing residual cardiovascular risk independently of lipid lowering.
Background: Despite intensive control of established coronary risk factors, such as dyslipidemia, hypertension, and diabetes, cardiovascular events continue to occur in high-risk patients. Residual risk attributable to chronic low-grade inflammation has therefore emerged as a major clinical concern.
Hara et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: